Browse AMR Mutations
Explore antimicrobial resistance mutations from the literature
Explore antimicrobial resistance mutations from the literature
Overview
Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis.
Study of fluoroquinolones resistance in rifampicin-resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes.
Assoc w R
Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum.
Molecular Epidemiology and Polymorphism Analysis in Drug-Resistant Genes in M. tuberculosis Clinical Isolates from Western and Northern India.
variable codons
Identification and quantification of gyrA variants in fluoroquinolone-resistant Mycobacterium tuberculosis in a MeltArray reaction.
All mutations are in the quinolone resistance-determining region (QRDR) of gyrA.
Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis.
A novel one-tube nested fluorescence melting curve analysis for rapid detection of drug-resistant Mycobacterium tuberculosis.
All mutations were confirmed by DNA sequencing.
Fluoroquinolone and Second-Line Injectable Resistance Among Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates: A Molecular Study from a High-Burden Setting.
mutations in gyrA are associated with fluoroquinolone resistance
Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis.
Mutations in gyrA are associated with fluoroquinolone resistance.
Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases.
Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review.
Mutations in gyrA are associated with fluoroquinolone resistance in Mycobacterium tuberculosis.
Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.
Mutations in gyrA QRDR correlate with increased MICs for fluoroquinolones.
The Genetic Background Modulates the Evolution of Fluoroquinolone-Resistance in Mycobacterium tuberculosis.
Most prevalent in high-frequency OFX-R strains.
Genomic Analysis of Mycobacterium tuberculosis Isolates and Construction of a Beijing Lineage Reference Genome.
The G88C mutation in gyrA was found in TCDC4 and TCDC10.
Genotypic and phenotypic drug resistance patterns of Mycobacterium tuberculosis isolated from presumptive pulmonary tuberculosis patients in Ethiopia: A multicenter study.
Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations.
Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis.
Pyrosequencing for rapid detection of tuberculosis resistance in clinical isolates and sputum samples from re-treatment pulmonary tuberculosis patients.
Molecular detection of rifampin, isoniazid, and ofloxacin resistance in Iranian isolates of Mycobacterium tuberculosis by high-resolution melting analysis.
High-resolution melting analysis for the rapid detection of fluoroquinolone and streptomycin resistance in Mycobacterium tuberculosis.
Mutations in gyrA were associated with fluoroquinolone resistance.
Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays.
Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis.
Mutations in gyrA confer resistance to fluoroquinolones
Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.
This mutation does not confer resistance and was excluded from the analysis.
Second-line anti-tuberculosis drug resistance testing in Ghana identifies the first extensively drug-resistant tuberculosis case.
Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones.
Mycobacterium tuberculosis gyrA conferring resistance to fluoroquinolones; CARD accession: CARD:3003295
A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics.
Mycobacterium tuberculosis gyrA conferring resistance to fluoroquinolones; CARD accession: CARD:3003295
Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.
Mycobacterium tuberculosis gyrA conferring resistance to fluoroquinolones; CARD accession: CARD:3003295
Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis.
Mycobacterium tuberculosis gyrA conferring resistance to fluoroquinolones; CARD accession: CARD:3003295
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.
Tuberculosis drug resistance mutation database.
No comments yet. Be the first to comment!
© 2026 ResLit. Data sourced from PubMed literature analysis.
Built for antimicrobial resistance research